Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)
Open Access
- 12 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 14 (3), 368-380
- https://doi.org/10.1093/neuonc/nor203
Abstract
The diagnosis of primary central nervous system lymphoma (PCNSL) by radiographical examination is often difficult because of its similarity to other brain tumors. To test whether interleukin-10 (IL-10) and IL-6 can be used to distinguish PCNSL from other brain tumors that are radiographically similar, cerebrospinal fluid (CSF) levels of IL-10 and IL-6 were measured in 66 patients with intracranial tumors (PCNSLs: 26 cases; other brain tumors: 40 cases). In the patients with PCNSLs, the median CSF levels of IL-10 and IL-6 were 27 pg/mL and 5.4 pg/mL, respectively. The CSF IL-10 and IL-6 levels were significantly higher in PCNSLs than in the other brain tumors. To validate the diagnostic value of CSF IL-10 in PCNSL, we prospectively examined 24 patients with brain lesions that were suspected to be PCNSL. We observed that the CSF IL-10 levels were significantly higher in PCNSLs than in other brain tumors. At an IL-10 cutoff level of 9.5 pg/mL, the sensitivity and specificity were 71.0% and 100%, respectively. After therapy, the CSF IL-10 levels were decreased in all patients and were increased at relapse in most of these patients. Immunohistochemically, all PCNSLs, except for 1 unclassified PCNSL, expressed both IL-10 and IL-10 receptor-A. In the patients with high CSF IL-10, IL-10 expression levels in tumor were relatively higher, compared with low CSF IL-10; however, there was no significant difference between these groups. In addition, elevated CSF level of IL-10 was significantly associated with having a shorter progression-free survival (hazard ratio, 3.37; 95% confidence interval, 0.985–11.528; log-rank, P= .038). These results indicate that the CSF level of IL-10 may be a useful diagnostic and prognostic biomarker in patients with PCNSLs.This publication has 50 references indexed in Scilit:
- Changes in Cerebrospinal Fluid Cytokine Expression in Tuberculous Meningitis Patients with TreatmentNeuroimmunomodulation, 2010
- Primary central nervous system lymphoma: Immunohistochemical profile and prognostic significanceNeuropathology, 2009
- Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP ChemotherapyClinical Cancer Research, 2009
- Interleukin‐10: new perspectives on an old cytokineImmunological Reviews, 2008
- Protein Biomarker Identification in the CSF of Patients With CNS LymphomaJournal of Clinical Oncology, 2008
- IL-10 Measurement in Aqueous Humor for Screening Patients with Suspicion of Primary Intraocular LymphomaInvestigative Ophthalmology & Visual Science, 2007
- Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomasBritish Journal of Haematology, 2007
- Clinical significance of serum Th1‐, Th2‐ and regulatory T cells‐associated cytokines in adult T‐cell leukemia/lymphoma: High interleukin‐5 and ‐10 levels are significant unfavorable prognostic factorsInternational Journal of Cancer, 2006
- Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistanceOncogene, 2004
- Primary intracerebral malignant lymphoma: report of 248 casesJournal of Neurosurgery, 2000